The Patent Finder
US

Substituted Quinazolines as Inhibitors of Kras G12C

US 11,878,985 In force
OverviewFamilyAssignmentsSources & methods

Term ends Oct 10, 2034 · High confidence

Filed Dec 17, 2020 as application 17/125,955 · Granted Jan 23, 2024
Base term plus 169 days of patent term adjustment (USPTO delay) · capped by a resolved terminal disclaimer
Today
20 years from filing
2014 2034
Clock starts
Oct 10, 2014
Term ends
Oct 10, 2034
Granted
Jan 23, 2024
base term Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
169
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
Capped
Terminal disclaimer
Resolved from the filed document, referencing US 9,840,516.
0 of 2
Maintenance fees paid
Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.
5
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.

This patent's term runs 169 days past its 20-year base term on prosecution delay. A terminal disclaimer resolved from the filed document caps it earlier. 0 of 2 maintenance fees are paid so far. Confidence: High. from the record

How we calculated this date

One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
StepInputDate after this stepConfidence
Base term, 20 years from filingClock starts Oct 10, 2014, when application 14/511,425, the earliest non-provisional in its chain, was filed (this one was filed Dec 17, 2020)Oct 10, 2034High confidence
Continuity chainEvery parent in the chain resolvedno changeHigh confidence
Patent term adjustment+169 days, USPTO patent term adjustment recordMar 28, 2035High confidence
Terminal disclaimer capDisclaimer resolved from the filed document (refs US 9,840,516)capped to Oct 10, 2034High confidence
Patent term extensionNone on fileno changeHigh confidence
Fee events0 of 2 maintenance fees paidIn forceHigh confidence
Computed term endThe steps above, in orderOct 10, 2034High confidence

This family

US 9,840,516In force
Oct 2034
Oct 2034
US 10,370,386In force
Oct 2034
Oct 2034
US 10,927,125In force
Oct 2034
Oct 2034
US 11,878,985this patent
Oct 2034
Oct 2034
Application 18/416,739Pending
not computed
not computed
Every application listed has its file history here. The family may have others.

Assignments

Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
RecordedAssignorAssigneeConveyance
Dec 28, 2021
Reel 58604, frame 4
Janssen Biotech, Inc.Araxes Pharma LLCAssignment of Assignor's Interest

Sources

Google Patents · The patent document at USPTO · Assignment records at USPTO

USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup

Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited